Sintilimab - CAS 2072873-06-2

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) .Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

PD-1/PD-L1

Cell Cycle/Checkpoint, Apoptosis, Immunology/Inflammation

2072873-06-2

>95%

-20°C

Ice Packs

Inhibitory Antibodies